Skip to main content

Eledon Pharmaceuticals, Inc.

ELDN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001404281

No open-market purchases or sales by Eledon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $184.6M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Eledon Pharmaceuticals, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of ELDN: Q3 2023 compared with Q4 2023
MeasureQ3 2023Of which not filed for Q4 2023Q4 2023Change
Holders28129+2
Shares8.92M13.0K9.15M+248.4K (+2.8%)
Value$12.2M$17.9K$16.5M+$4.28M (+35.1%)

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (5)

Institutions that held Eledon Pharmaceuticals, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to ELDN in Q4 2023
InstitutionSharesValue% of portfolio
Citadel Advisors LLC23,208$41.8K0.00%
Pathstone Holdings, LLC13,029$23.5K0.00%
Two Sigma Securities, LLC11,780$21.2K0.00%
UBS Group AG556$1.00K0.00%
Bank of America Corp15$270.00%

Sold out (3)

Institutions that held Eledon Pharmaceuticals, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of ELDN in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
SVB Financial Group13,472$18.5K
Two Sigma Advisers, LP13,100$17.9K
RMB Capital Management, LLC10,000$13.7K

Not filed for Q4 2023 yet (1)

Institutions that held Eledon Pharmaceuticals, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ELDN in Q3 2023 that haven't filed for Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Pathstone Family Office, LLC13,029$17.9K